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Diabetes and Increased Lipid Peroxidation are Associated with Systemic
Inflammation Even in Well-Controlled Patients
Abstract

Background
The effect of the interaction between type 2 diabetes and dyslipidemia on inflammation and lipid
peroxidation (LPO) has not been assessed.

Aim
To investigate whether diabetes coupled with dyslipidemia alters oxidative metabolism leading to
increased LPO products and inflammatory status.

Methods
100 patients were divided into four groups based upon diabetic and dyslipidemic status: poorly controlled
diabetes with dyslipidemia (DM-PC/D), well-controlled diabetes with dyslipidemia (DM-WC/D),
normoglycemic individuals with dyslipidemia (NG/D), and normoglycemic individuals without
dyslipidemia (NG/ND). Plasma was evaluated for an LPO product (MDA), antioxidant levels and
inflammatory cytokines.

Results
Diabetics presented significantly higher levels of LPO (p < 0.05) and the DM-PC/D had higher levels of
proinflammatory cytokines and MDA in the plasma in comparison with normoglycemics (p < 0.05).
Interestingly IL1-β, IL-6, and TNF-α in DM-WC/D were not statistically different from those in DM-PC/D.
Normoglycemic individuals with dyslipidemia presented significantly increased levels of IL-6 and TNF-α
when compared to normoglycemic without dyslipidemia (p < 0.05). MDA levels were also positively
correlated with the presence of DM complications (r = 0.42, p < 0.01).

Conclusions
These findings show that dyslipidemia is associated with an increased inflammatory status, even in wellcontrolled diabetics and in normoglycemics. Our results suggest that lipid metabolism and peroxidation
are important for the development of inflammation, which is elevated in several complications associated
with diabetes.
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Abstract
Background—The effect of the interaction between type 2 diabetes and dyslipidemia on
inflammation and lipid peroxidation (LPO) has not been assessed.
Aim—To investigate whether diabetes coupled with dyslipidemia alters oxidative metabolism
leading to increased LPO products and inflammatory status.
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Methods—100 patients were divided into four groups based upon diabetic and dyslipidemic
status: poorly controlled diabetes with dyslipidemia (DM-PC/D), well-controlled diabetes with
dyslipidemia (DM-WC/D), normoglycemic individuals with dyslipidemia (NG/D), and
normoglycemic individuals without dyslipidemia (NG/ND). Plasma was evaluated for an LPO
product (MDA), antioxidant levels and inflammatory cytokines.
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Results—Diabetics presented significantly higher levels of LPO (p < 0.05) and the DM-PC/D
had higher levels of proinflammatory cytokines and MDA in the plasma in comparison with
normoglycemics (p < 0.05). Interestingly IL1-β, IL-6, and TNF-α in DM-WC/D were not
statistically different from those in DM-PC/D. Normoglycemic individuals with dyslipidemia
presented significantly increased levels of IL-6 and TNF-α when compared to normoglycemic
without dyslipidemia (p < 0.05). MDA levels were also positively correlated with the presence of
DM complications (r = 0.42, p < 0.01).
Conclusions—These findings show that dyslipidemia is associated with an increased
inflammatory status, even in well-controlled diabetics and in normoglycemics. Our results suggest
that lipid metabolism and peroxidation are important for the development of inflammation, which
is elevated in several complications associated with diabetes.

Author Manuscript
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1. Introduction

Author Manuscript

Diabetes is a group of metabolic diseases that leads to impaired wound healing (Goova et al.,
2001), higher susceptibility to infections (Hirsch et al., 2008), atherosclerosis (Halliwell,
2000), micro- and macrovascular alterations (Ahmed, 2005; Mooradian, 2009; Velazquez,
Winocour, Kesteven, Alberti, & Laker, 1991) even in diabetic patients with optimized
glycaemic control (Chello et al., 2009). Inflammation is an underlying cause of several comorbidities associated with poorly controlled diabetes (Mirza et al., 2012) and several
studies have demonstrated high levels of circulating inflammatory cytokines such as
interleukin-6 and tumor necrosis factor α (TNF-α) (Mirza et al., 2012; Pickup, Chusney,
Thomas, & Burt, 2000; Rytter et al., 2009; Vinik, 2005; Wisse, 2004) in type 2 diabetic
patients.

Author Manuscript

Several mechanisms can contribute to the systemic hyperinflammatory status in diabetes,
including dyslipidemia that modulates the function and activity of myeloid cells, and the
increase of oxidative metabolism with enhanced production of reactive oxygen species
(ROS) (Millar, Phan, & Tibbles, 2007). As a defense mechanism cells produce antioxidants
(AOs) that prevent or limit oxidative tissue injury (Chapple & Matthews, 2007; StosicGrujicic, Miljkovic, Cvetkovic, Maksimovic-Ivanic, & Trajkovic, 2004). Overproduction of
ROS may result in an imbalance between ROS and AOS leading to oxidative stress and
damage (Chapple & Matthews, 2007; Niedowicz & Daleke, 2005) that can contribute to
injury of the host tissue by several mechanisms, including DNA damage, peroxidation of
lipid membranes, oxidation of enzymes and stimulation of proinflammatory cytokines
(Devaraj, Venugopal, Singh, & Jialal, 2005; Li, Huang, & Shen, 2014).
In spite of the biological rationale, there is paucity of information on the relationship
between metabolic control in diabetes mellitus and the status of lipid metabolism
(dyslipidemia), lipid peroxidation and antioxidant capacity as modulators of systemic
inflammation in the same individual. The aim of this study is to determine whether type 2
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diabetes, dyslipidemia and increased lipid peroxidation are specifically associated with
aggravated systemic inflammation.

2. Materials and methods
2.1. Subjects
The present cross-sectional study, approved by the Human Research Ethics Committee of
the School of Dentistry at Araraquara (UNESP–Univ. Estadual Paulista, Araraquara, Brazil;
Protocol number 50/06), was conducted according to the ethical principles of the
Declaration of Helsinki. Data collection was carried out between May 2009 and November
2010. All volunteers were informed about the aims and methods of this study, and they
provided their written consent to participate.

Author Manuscript

Patients with type 2 diabetes mellitus (T2DM) were recruited from local outpatient diabetic
clinics, regional community hospitals, and physicians' offices. Normoglycemic individuals
were consecutively selected from the list of patients who voluntarily sought dental treatment
at the School of Dentistry at Araraquara, Univ. Estadual Paulista (UNESP), Brazil, at the
same time as the DM2 group.
A simple questionnaire was applied initially to all subjects to identify the patients that were
eligible to be enrolled in the study, considering the inclusion/exclusion criteria. All study
participants ranged in age from 35 to 60 years and had similar socio-economic level. None
of the patients were pregnant or were current or former smokers. Patients taking antibiotic,
nonsteroidal anti-inflammatory, hormones or hypolipidemic drugs such as statins or fibrates,
were excluded from the study. Particular care was taken to exclude subjects with history of
anemia and diseases known to influence lipoprotein metabolism, such as hypothyroidism.

Author Manuscript

A power analysis based on a pilot study determined that at least 25 patients in each group
would be sufficient to detect a 3-unit difference in MDA levels or a 2.4-unit difference in an
inflammatory cytokine with 90% power and 95% confidence interval. The population was
divided into four groups based upon diabetic and dyslipidemic status: poorly controlled
diabetics with dyslipidemia (DM-PC/D), well-controlled diabetics with dyslipidemia (DMWC/D), normoglycemic individuals with dyslipidemia (NG/D), and healthy individuals
(NG/ND). Post hoc power calculation (at the 95% significance level, p = 0.05) showed that
all comparisons had a power > 0.8 except for hsCRP (0.56), triglycerides (0.65), and
abdominal circumference (0.18).
2.2. Clinical record and physical evaluation

Author Manuscript

After enrolling in the study, all participants answered a face-to-face structured questionnaire
about socio-demographic data, personal and family medical history, and use of medications.
A trained examiner collected information from diabetic patients regarding time since
diabetes onset, medication used to control glucose, and the presence of complications
associated with diabetes. Subjects completed a physical examination including
anthropometric data such as abdominal circumference (cm), hip (cm), waist (cm), height
(m), weight (kg) and body mass index (BMI).
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2.3. Laboratory measurements: metabolic control and lipoprotein profile
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Blood samples were collected after a 12-h overnight fast to evaluate blood cell counts (white
and red series), fasting plasma glucose (mg/dl) by modified Bondar and Mead method,
glycated hemoglobin (HbA1c) by enzymatic immunoturbidimetry, insulin levels by the
chemiluminescence immunoassay, high-sensitivity C-reactive protein by the nephelomeric
method and lipid profile (total cholesterol (TC), triglycerides (TGs), and HDL) by enzymatic
methods. LDL was determined by the Friedewald formula. The same laboratory performed
all analyses.

Author Manuscript

To avoid the inclusion of individuals with transitory dyslipidemia, the cutoff points used
were the highest values according to the National Cholesterol Educational Program (NCEP)
Adult Treatment III (ATP III) (NCEP, 2002): TC ≥ 240 mg/dl, LDL ≥ 160 mg/dl, HDL ≤ 40
mg/dl, and TGs ≥ 200 mg/dl. Metabolic control was considered as inadequate when HbA1c
≥ 8.5% and these patients were included in the DM-PC/D Group (Diabetes Poorly
Controlled with Dyslipidemia). When HbA1c < 7.0% the metabolic control was considered
as adequate and these patients were included in the DM-WC/D (Diabetes Well-controlled
with Dyslipidemia). The homeostasis model assessment of insulin resistance (HOMA IR)
was calculated by the formula: fasting insulin concentration (µU/ml) × fasting glucose
concentration (mmol/L) divided by 22.5 (Matthews et al., 1985).
2.4. Sample collection
Blood samples were collected in tubes with EDTA centrifuged at 3000 × g for 10 min at
4 °C, promptly aliquoted and stored at −80 °C until the analyses. The following assays were
performed by professionals unaware of the experimental groups.

Author Manuscript

2.5. Analysis of cytokines in plasma
Eleven cytokines (interleukin-1β [IL-1β], IL-2, -4, -5, -6, -7, -8, -10, -12 (p70) and -13 and
tumor necrosis factor-alpha [TNF-α]) were measured in plasma samples by multiplex beads
(Bio-Plex system, Bio-Rad Laboratories, Hercules, CA, USA), following the manufacturer's
instructions.
2.6. Lipid peroxidation and antioxidant assays
2.6.1. MDA assay—The assessment of MDA in plasma was determined by HPLC
(Shimadzu, Tokyo, Japan) with a reverse-phase HPLC column (C18; 4.6 × 150 mm)
(Phenomenex, Torrance, CA, USA) and compared with MDA standard curves. Plasma
samples were prepared as described previously (Hong, Yeh, Chang, & Hu, 2000).

Author Manuscript

2.6.2. Antioxidant assay—The levels of total antioxidant capacity of plasma were
evaluated with a commercially available colorimetric kit (Cayman Chemical Company®,
Ann Arbor, MI, USA) following the manufacturer's instructions. The absorbance at 750 nm
was measured by spectrophotometry using a plate reader and the results were expressed as
Trolox (mM).
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2.7. Statistical analysis
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The distribution and normality of the variables were evaluated by the D'Agostino–Pearson
test. Subsequently, the general characteristics of each group were described as mean and
standard deviation (SD); the cytokines expression in plasma were expressed as median
(25%/75% quartiles) in Table 1 and as mean and standard deviation (SD) in Fig. 2. The
differences between the groups for parametric data were evaluated by ANOVA followed by
Bonferroni's post-test, and non-parametric data were evaluated by the Kruskall–Wallis test,
followed by Dunn's post-test. Correlations were analyzed by the Pearson rank test adjusting
for age, gender, and BMI. To determine the influence of lipid peroxidation and diabetic
status on the expression of plasma cytokines, separate multivariable logistic and linear
regression models were built for each independent variable. Variables found to be associated
with the independent and dependent variables, and thus possible confounding factors, were
included in the models. Moreover, regardless of their statistical significance, all variables
known to have biologic linkage with the outcomes were retained. Based on previous studies
(Carey et al., 2004; Fentoglu et al., 2009), correlation and regression models were adjusted
for age, gender, BMI, and triglycerides, considered important as possible confounders in
establishing the relationship among the variables of interest. The significance level was set at
α = 0.05. All analyses were carried out with SPSS software, IBM version 19.

3. Results
3.1. Sample population

Author Manuscript
Author Manuscript

The general characteristics of the sample population are shown in Table 1. From the
screened patients, 100 were identified as meeting the study inclusion criteria; of these, 25
patients were assigned to one of four different groups. There was no statistically significant
difference among the participants with respect to gender, age and socioeconomic status. In
relation to physical evaluation, all individuals were overweight and the diabetic groups were
obese and presented higher values of BMI (p < 0.05), waist/hip proportion and abdominal
circumference. The groups with diabetes had significantly increased levels of fasting
glucose, HbA1c, and insulin resistance compared with normoglycemic patients. Based on
ATP III (NCEP, 2002) definition of dyslipidemia, groups DM-PC/D, DM-WC/D and NG/D
were dyslipidemic presenting increased levels of total cholesterol, LDL cholesterol, and
triglycerides compared with group NG/ND (healthy individuals) (p < 0.05). The evaluation
of total and differential counting of cells (white and red series) showed a statistical
difference between poorly controlled diabetic/dyslipidemic patients regarding white blood
cells (total leucocytes, neutrophils and lymphocytes) and healthy individuals (p < 0.05).
There was no difference in time since diabetes onset (years) between poorly controlled/
dyslipidemic (6.5 ± 4.5) and well-controlled/dyslipidemic diabetics (5.5 ± 7.1). Regarding
diabetic complications, 60% of the poorly controlled diabetics and 40% of the wellcontrolled diabetics presented at least one complication related to type 2 DM. This
difference was significant (p < 0.05), with the most common complication being retinopathy,
followed by nephropathy. A total of 17 patients from DM-PC/D were treated with oral
antidiabetic agents, 1 patient was treated with insulin therapy, and 7 were treated with the
combination of insulin and antidiabetic agents. From the group DM-WC/D, 12 patients were
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treated with oral antidiabetic agents, 1 was treated with insulin therapy, 4 were treated with
the combination of insulin and antidiabetic agents and 8 were treated with no drug therapy.
3.2. Lipid peroxidation levels

Author Manuscript

3.2.1. Plasma malondialdehyde (MDA)—Plasma MDA levels were slightly increased
in all dyslipidemic patients, regardless of their glycemic status. The highest level of plasma
MDA was observed in poorly controlled diabetics with dyslipidemia who had about 2.9
times higher MDA levels when compared with those in the normoglycemic groups (p <
0.05) and approximately 1.6 times higher MDA levels when compared with well-controlled
diabetics with dyslipidemia (p < 0.05) (Fig. 1). Well-controlled diabetics with dyslipidemia
(DM-WC/D) presented significantly increased levels of MDA (p < 0.05) when compared
with those in the normoglycemic groups (NG/D and NG/ND). Normoglycemic individuals
with dyslipidemia had no increase in MDA levels compared to normoglycemic individuals
without dyslipidemia (p > 0.05) indicating that the presence of hyperglycemia played a
critical role in the increased MDA.
3.2.2. Antioxidant assay results—The levels of total antioxidant capacity of plasma
were expressed as mean (± SD) and showed increased values in the groups without type 2
diabetes (NG/ND: 0.69 (± 0.18) and NG/D: 0.66 (± 0.21)) and in the well-controlled
diabetics (DM-WC/D: 0.66 (± 0.18)). The group with poorly controlled diabetes with
dyslipidemia (DM-PC/D), presented the lowest levels of plasma antioxidant capacity.
However this difference was not significantly different between any of the groups (p > 0.05)
(Table 1).
3.3. Systemic inflammation

Author Manuscript

Overall, the expression of proinflammatory cytokines gradually increased from NG/ND,
NG/D, DM-WC/D, DM-PC/D (p < 0.05) indicating that diabetes significantly enhances the
systemic level of inflammation. The cytokines’ expression in plasma were expressed as
median (25%/75% quartiles) in Table 1 and as mean and standard deviation (SD) in Fig. 2.
The cytokines that are typically considered adipokines such as IL-6 and TNF-α were also
significantly increased in the groups with dyslipidemia in comparison with the group
without dyslipidemia.
3.4. Statistical analysis

Author Manuscript

3.4.1. Correlation analysis—Table 2 shows the adjusted correlation among diabetes
status, lipoprotein profile, anthropometric and lipid peroxidation markers, and plasma
cytokine expression taking into account the effect of age, gender and BMI. There was a wide
range of moderate positive correlations observed among diabetic status, lipid peroxidation
markers and expression of proinflammatory cytokines. Among the most significant
correlations were IL1-β with the following: fasting glucose (0.48), HbA1c (0.40) and MDA
(0.50); all of which were significant (p < 0.0001). Moderate positive significant correlation
was also observed among TNF-α and: fasting glucose (0.50), HbA1c (0.50), triglycerides
(0.35) and MDA (0.44) (p < 0.0001). Diabetes was significantly associated with lipid
peroxidation markers, and there was a strong positive correlation observed between MDA
and HbA1c (r = 0.643, p < 0.0001), suggesting that poor metabolic control is associated with
J Diabetes Complications. Author manuscript; available in PMC 2016 November 23.
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higher expression of MDA. The presence of complications related to type 2 diabetes mellitus
(T2DM), with the most common complication being retinopathy, followed by nephropathy
was positively correlated with HbA1c levels (r = 0.45, p < 0.01), MDA (r = 0.42, p < 0.01),
diabetes duration (r = 0.47, p < 0.001) and TNF-α (r = 0.35, p < 0.05). Significant positive
correlations (p < 0.05) were observed between insulin resistance (HOMA IR) and IL-6
(0.21), TNF-α (0.25) and between triglycerides and IL-1 (0.20), IL-6 (0.24) and TNF-α
(0.35). Besides, a significant positive correlation was observed between adipocytokines and
lipoprotein profile, such as IL-6 and triglycerides (0.24), IL-6 and total cholesterol (0.25)
and TNF-α and triglycerides (0.35).

Author Manuscript

The possible linkage among inflammation, diabetes, and lipid peroxidation is demonstrated
by a multiple regression analysis using separate models for independent variables. Lipid
peroxidation markers and diabetic status were directly related to the expression of
inflammatory cytokines, especially IL-1β (β = 0.40) and TNF-α (β = 0.50). IL-6 was
significantly related to lipoprotein profile rather than diabetic or inflammatory status (Table
3).

Author Manuscript

3.4.2. Regression analysis—To further define the influence of lipid peroxidation, poor
metabolic control and lipoprotein profile on increased levels of systemic inflammation, a
logistic regression was performed taking into account the effects of age, gender and BMI.
There was an approximate 3.2-, 2.0-, 1.9- and 2.6-fold increase in the odds of having
elevated levels of IL-1β, IL-6, IL-8, and TNF-α, respectively, among those patients who
have higher plasmatic levels of MDA (p < 0.05). In addition, increased levels of HbA1c were
associated with a ~ 1.5-fold increase in the odds ratio of high of IL-1β, IL-8, and TNF-α (p
< 0.05). In respect to lipoprotein profile and the relationship with increased expression of
inflammatory cytokines, only elevated triglycerides were associated with a ~ 1.5-fold
increase in the odds of high of IL-1β, IL-6, TNF-α and IL-4 (p < 0.05) and abdominal
circumference increased the odds of having elevated IL-8 and TNF-α (Table 4).

4. Discussion
In the present study we investigated whether type 2 diabetes mellitus (T2DM) coupled with
dyslipidemia was associated with altered oxidative metabolism and increased lipid
peroxidation and whether they were linked to greater systemic inflammation. Our results
indicate that diabetes associated with dyslipidemia, even in well-controlled patients, was
associated with increased lipid peroxidation. Furthermore, dyslipidemia and increased lipid
peroxidation were strongly correlated with higher levels of systemic inflammation.

Author Manuscript

Previous studies evaluated cytokines in plasma of patients with diabetes (Arnalich et al.,
2000; Mirza et al., 2012; Pickup et al., 2000) and their association with diabetic
complications (Liu et al., 2010; Ridker et al., 2000). However to the best of our knowledge,
this is the first study to establish a relationship between type 2 diabetes mellitus (T2DM) and
dyslipidemia and their impact on lipid peroxidation levels and systemic inflammation.
Elevated proinflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) were detected in diabetic
patients and the presence of complications, such as retinopathy and nephropathy, was
positively associated with increased levels of TNF-α. The anti-inflammatory cytokine IL-4
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was also elevated in diabetic patients. Interestingly, the levels of proinflammatory cytokines
(IL1-β, Il-6, TNF-α) in well-controlled diabetics with dyslipidemia were not statistically
different from those of poorly controlled diabetics with dyslipidemia. These findings suggest
that dyslipidemia might be one of the driving forces for elevated systemic inflammation even
in well-controlled diabetics.

Author Manuscript

It is known that obesity promotes dyslipidemia and may impact insulin action via additional
pathways, including the release of leptin, IL-6 and TNF-α (Vinik, 2005). In the present
study, diabetic individuals were considered obese if they had BMI > 30 and a large waist
circumference compared to healthy patients. Abdominal circumference statistically
increased the odds of having elevated IL-8 and TNF-α. Besides, patients with type 2
diabetes had an increased insulin resistance index (HOMA IR) compared to healthy patients
and significant associations were observed between insulin resistance (HOMA IR) and
cytokines (IL-6 and TNF-α). This fact is in accordance with previous studies that
demonstrated the association between insulin resistance and the increased expression of
inflammatory cytokines (Vinik, 2005; Wisse, 2004).
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The pathogenesis of diabetic dyslipidemia is not completely elucidated, although it is
recognized that lipid abnormalities are a primary feature of metabolic syndrome and can
precede the clinical manifestation of hyperglycemia (Davi et al., 2003; Ginsberg, 1991;
Haffner, 2002; Kreisberg, 1998). It is important to note that even with the well-established
effect of dyslipidemia on type 2 diabetes (Chisolm, Irwin, & Penn, 1992; Haffner, 2002;
Krauss & Siri, 2004; Kreisberg, 1998) several studies with diabetic populations do not take
into consideration the serum lipid characteristics of the population (Davi et al., 2003;
Esposito et al., 2002; Liu et al., 2010; Pandey, Mishra, & Rizvi, 2010; Pickup et al., 2000) or
the level of dyslipidemia (Cakatay, 2005; Esposito et al., 2002; Hussein et al., 2007; Mirza et
al., 2012; Nakhjavani et al., 2010; Van Guilder, Hoetzer, Greiner, Stauffer, & Desouza,
2006). In the present study we evaluated the lipid profile of the whole population and
included in dyslipidemic groups only patients with values consistent with an established
dyslipidemia (NCEP, 2002). There was an elevated inflammatory status in normoglycemic
dyslipidemic individuals (NG/D). This group presented significantly increased levels of IL-6
and TNF-α when compared to normoglycemic without dyslipidemia (NG/ND), suggesting
that dyslipidemia itself can increase the release of proinflammatory cytokines. In addition, a
positive correlation was observed between adipocytokines, IL-6 and TNF-α and
triglycerides and total cholesterol.

Author Manuscript

A limitation of many studies evaluating diabetic individuals is the lack of attention
concerning metabolic and dyslipidemic status, not separating the patients based on
dyslipidemia and controlled/poorly controlled type 2 diabetes mellitus, based on recent and
updated HbA1c levels (Cakatay, 2005; Gambino et al., 2004; Hussein et al., 2007;
Kostolanska, Jakus, & Barak, 2009; Rytter et al., 2009). We analyzed the DM patients as
separate groups based on the quality of metabolic control. As expected we observed a
significant increase in lipid peroxidation and proinflammatory cytokines in poorly controlled
diabetics when compared to the other groups, consistent with other reports (Chisolm et al.,
1992; Colas et al., 2010; Dennis et al., 2010; Gambino et al., 2004; Hussein et al., 2007;
Mirza et al., 2012; Nishigaki, Hagihara, Tsunekawa, Maseki, & Yagi, 1981; Nishimura,
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Iwamoto, & Soga, 2007; Sundaram et al., 1996). However, analysis of the data considering
the metabolic status and lipid profile allowed us to observe novel findings related to the
impact of dyslipidemia on the level of systemic inflammation in well-controlled diabetics.

Author Manuscript
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Well-controlled diabetics are usually considered at a lower risk to develop cardiovascular
disease and diabetic complications when compared to patients with inadequate metabolic
control (American Diabetes, A, 2015; NCEP, 2002). For this reason lipid profile and levels
of acute phase proteins are not usually evaluated in these patients. Interestingly, in the
present study, well-controlled diabetics with dyslipidemia (DM-WC/D) showed significantly
the highest levels of high sensitivity C-reactive protein. This unexpected finding could
probably be due to the fact that this group also presented significantly increased measures of
abdominal circumference (Hak et al., 1999; Lakka, Lakka, Salonen, Kaplan, & Salonen,
2001; Mendall et al., 2000). However, in the present study the statistical analysis did not
show significant correlation between C-reactive protein and abdominal circumference after
the adjustment for age, gender and BMI. The DM-WC/D group also showed high levels of
lipid peroxidation and proinflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α). Thus, the
inflammatory and lipid peroxidation levels of the well-controlled diabetics were more
similar to those of the poorly controlled diabetics and markedly higher than to those of the
normoglycemic group with dyslipidemia. This shows the importance of better evaluation of
these patients even if they are considerated well-controlled diabetics and also suggests that
increased lipid peroxidation and systemic inflammation may represent a possible risk for the
development of complications and imbalance in the metabolic control. In support to this
possibility, other studies have also emphasized the hypothesis that lipid peroxidation
contributes to the initiation and progression of diabetes (Giugliano, Ceriello, & Paolisso,
1996; Van Dam et al., 1995) and that oxidative stress can be an important early event in the
pathogenesis of complications secondary to diabetes (Sasaki & Inoguchi, 2012) and may
indicate an underlying subclinical pathology despite the good metabolic control (Cakatay,
2005). We add to these findings that lipid peroxidation is positively associated with
complications related with type 2 diabetes and also with systemic inflammation, particularly
IL-1β and TNF-α.
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The cross-sectional design of the present study limited the interpretation of our findings.
Thus, the temporal sequence showing whether diabetes coupled with dyslipidemia precedes
the increased systemic inflammation or vice versa is not known. Nonetheless, the present
study intended to assess the direction of the association as to whether diabetes coupled with
dyslipidemia leads to increase in systemic inflammation. In an effort to minimize the
influence of lifestyle behaviors and the effects of confounding factors, particular care was
taken to use strict inclusion criteria, having subjects of similar socioeconomic level, age and
gender-matched, who were not currently taking medication that could influence
inflammatory and oxidative markers (i.e., statins). Nevertheless, our study suggests that
increased lipid peroxidation aggravates systemic inflammation even in well-controlled
diabetics and normoglycemic dyslipidemic patients.
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5. Conclusion
In conclusion, our study suggests that lipid peroxidation may represent an additive effect to
the metabolic imbalance associated with type 2 diabetes, increased systemic inflammation
and the development of diabetes-associated complications. In this sense, dyslipidemia may
have a relevant impact on systemic inflammation via altered oxidative metabolism leading to
increased lipid peroxidation even in well-controlled diabetics.
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Fig. 1.
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Lipid Peroxidation expression in plasma: Levels of MDA (µM). Data are presented as mean
SD (**p < 0.0001 in relation to groups 2, 3 and 4; *p < 0.05 in relation to groups 3 and 4;
ANOVA Test; α = 5%).
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Fig. 2.

Cytokines’ expression in plasma (pg/ml). Data are presented as mean and standard deviation
(SD) (**p < 0.0001 in relation to group 4; *p < 0.05 in relation to group 4; #p < 0.05 in
relation to group 3; Kruskall–Wallis Test; α = 5%).

Author Manuscript
Author Manuscript
J Diabetes Complications. Author manuscript; available in PMC 2016 November 23.

de Souza Bastos et al.

Page 15

Table 1

Author Manuscript

Characteristics of the sample: demographic, physical, laboratory, antioxidants and cytokines data.
DM-PC/D
(DM ≥ 8.5%/with
dyslip)

DM-WC/D
(DM < 7.0%/with
dyslip)

NG/D
(normoglycemic/with dyslip)

NG/ND
(normoglycemic/without dyslip)

Gender (F/M)

14/11

15/10

14/11

15/10

Age

47.8 (± 7.7)

50.3 (± 6.7)

49.1 (± 7.9)

45.6 (± 5.3)

30.8 (± 4.1)#

30.9 (± 4.1)#

28.5 (± 4.0)

27.6 (± 6.9)

Abdominal circumference

103.7 (± 14.3)

107.9 (± 10.0)#,§

98.2 (± 10.7)

98.1 (± 18.0)

Waist/hip ratio

1.0 (± 0.1)

1.0 (± 0.1)

0.9 (± 0.1)

0.9 (± 0.1)

Fasting glucose (mg/dL)

233.4 (± 76.6)†,‡

137.7 (± 43.5)‡

90.2 (± 6.1)

91.0 (± 7.5)

HbA1c (%)

10.7 (± 1.8)**

6.5 (± 0.7)§,#

5.5 (± 0.7)

5.2 (± 0.6)

Insulin (U/L)

17.7 (± 14.5)#

16.2 (± 7.8)#

12.5 (± 8.3)

12.1 (± 13.7)

HOMA IR Index

9.8 (± 8.5)‡

5.4 (± 2.7)§,#

2.8 (± 1.8)

2.8 (± 3.4)

Total cholesterol (mg/dL)

244.0 (± 38.5)##

247.3 (± 44.3)##

244.8 (± 41.9)##

173.9 (± 18.4)

HDL cholesterol (mg/dL)

45.9 (± 9.8)

47.2 (± 10.6)

50.0 (± 11.3)

48.9 (± 13.4)

LDL cholesterol (mg/dL)

153.6 (± 39.0)##

150.8 (± 45.1)##

157.0 (± 43.2)##

105.5 (± 17.8)

Triglycerides (mg/dL)

218.1 (± 94.2)##

246.2 (± 108.4)##

189.1 (± 82.7)##

94.1 (± 37.8)

Hs C-Reactive Protein
(mg/dL)

0.4 (± 0.3)

0.7 (± 0.5)#

0.4 (± 0.3)

0.4 (± 0.6)

White blood Cells (mm3)

7.403 (± 1.687)##

7.144 (± 1.932)

6.886 (± 1.814)

5.903 (± 1.503)

Red blood cells (× 106)

4.9 (± 0.4)

4.7 (± 0.5)

4.9 (± 0.4)

4.6 (± 0.5)

Antioxidants (mM)

0.60 (± 0.20)

0.66 (± 0.18)

0.66 (± 0.21)

0.69 (± 0.18)

IL-1β (pg/ml)

0.48 (0.39/0.82)§,##

0. (0.39/0.60)##

0.41 (0.32/0.45)

0.35 (0.29/0.38)

IL-2 (pg/ml)

0.39 (0.0/0.71)

0.39 (0.22/0.49)

0.26 (0.0/0.48)

0.33 (0.22/0.42)

IL-4 (pg/ml)

0.67 (0.44/1.0)#

0.42 (0.22/1.0)

0.44 (0.26/0.82)

0.37 (0.15/0.45)

IL-5 (pg/ml)

1.28 (1.17/1.64)#

1.36 (1.09/1.5)

1.2 (1.04/1.4)

1.14 (1.0/1.28)

IL-6 (pg/ml)

1.57 (1.27/2.04)#

1.57 (1.19/1.8)#

1.41 (1.2/1.8)#

1.01 (0.54/1.3)

IL-7 (pg/ml)

1.14 (1.01/1.36)

1.14 (1.0/1.4)

1.06 (0.9/1.4)

1.0 (0.85/1.2)

IL-8 (pg/ml)

2.54 (2.0/3.0)##

2.16 (1.84/2.82)#

2.25 (1.8/2.5)

1.88 (1.4/2.1)

IL-10 (pg/ml)

0.71 (0.6/0.8)

0.74 (0.6/1.0)

0.71 (0.63/0.82)

0.64 (0.6/0.7)

IL-12 (p70) (pg/ml)

0.99 (0.3/1.1)

0.90 (0.7/1.0)

0.90 (0.3/1.0)

0.90 (0.7/1.1)

IL-13 (pg/ml)

1.93 (1.3/2.9)

1.85 (1.2/2.5)

2.0 (1.4/2.9)

1.7 (1.3/2.5)

TNF-α (pg/ml)

5.68 (4.5/7.0)§,##

5.0 (4.0/6.2)##

4.56 (3.9/4.1)#

2.68 (1.5/4.2)

BMI

(m/kg2)

Author Manuscript
Author Manuscript

Data are presented as mean SD or median (25th/75th percentile).

Author Manuscript

#

p < 0.05 in relation to group 4;

##

p < 0.0001 in relation to group 4;

§

p < 0.05 in relation to group 3;

†

p < 0.05 in relation to group 2;
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‡

p < 0.0001 in relation to groups 3 and 4;

**

p < 0.0001 in relation to the other groups (Kruskal–Wallis Test; α = 5%).
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0.06

Abdominal circunf
0.25*

0.05

0.10

0.03

0.28*

0.001

0.11

− 0.01

0.15

0.04

− 0.01

0.12

0.04

0.25*

0.24*

IL-5

0.16

0.12

0.17

0.08

Adjusted for age, gender and BMI.

a

0.25*
0.08

0.02

0.12

0.20*
0.08

− 0.03

0.01

− 0.01

− 0.11

− 0.03

− 0.02

0.09

0.15

IL-10

− 0.01

0.16

− 0.05

0.21*
0.24*

− 0.03

0.02

0.15

0.17

0.32**

IL-8

− 0.17

0.25*

0.21*

0.19

0.17

IL-6

HbA1c, glycated hemoglobin; HOMA IR, homeostatasis model assessment of insulin resistance.

0.50**

0.15

Wais/hip proportion

MDA (µM)

0.04

0.10

0.20*

Triglycerides (mg/dL)
BMI

− 0.01

0.14

LDL-cholesterol (mg/dL)

0.04

− 0.15

HDL-cholesterol (mg/dL)

0.05

0.20*

0.12

Total Cholesterol (mg/dL)

0.18

0.21*

0.40**

HbA1c
HOMA IR index

0.30**

IL-4

0.48**

IL-1β

Fasting glucose (mg/dL)

p < 0.0001 (r; Pearson's correlation coefficient; α = 5%).

**

p < 0.05;

*

Lipid peroxidation markera

Physical Parametersa

Lipoprotein profilea

Diabetic statusa

Parameter

0.44**

0.04

0.14

0.05

0.35**

0.07

− 0.08

0.16

0.25*

0.50**

0.50**

TNF-α

Adjusted correlation between plasma cytokines and diabetes status, lipoprotein profile, physical parameters, lipid peroxidation levels markers.
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0.12

Abdominal circ

0.21

TGL
0.04

0.14

LDL

BMI

0.2

Total Chol

0.18

0.24*

0.19

0.33

− 0.004

0.051

0.37**

0.008

0.17

0.27*

0.13

0.50**

0.47 **

0.44**

TNF-αa β

0.09

0.03

0.10

− 0.003

0.05

0.12

− 0.01

0.20*

0.28*

0.24*

IL-4a β

Adjusted for age, gender and BMI.

a

LPO, lipid peroxidation; MDA PL, malondialdehyde in plasma; HbA1c (glycated hemoglobin); HOMA IR, Insulin resistance.

β partial standardized regression coefficient. 95%CI.

p < 0.0001.

**

p < 0.05;

*

− 0.04

0.21*

− 0.005

0.03

0.26*

0.08

0.01

0.01

Insulin

0.23*

0.2

HOMA IR

0.18
0.17

0.17

0.40**

HbA1c

0.11

0.25*

IL-8a β

0.2

0.17

0.50**

Fasting glucose

Bold type indicates that the association reached statistical significance

Physical parameters

Lipoprotein profile

Diabetes status

0.15

0.50**

LPO parameter

MDA PL

IL-6a β

IL-1βa β

Independent variables (separate models)

Multiple Regression Linear model with the influence of lipid peroxidation, diabetes status, lipoprotein profile and physical parameters on plasma
cytokines.
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1.16 (0.97–1.38)
1.02 (0.95–1.10)

1.31* (1.09–1.58)
1.12* (1.02–1.24)
1.00 (0.98–1.03)

HbA1c
HOMA IR
Insulin

0.97 (0.89–1.07)
1.06 (1.00–1.14)

Abdominal circ

1.04 (0.96–1.13)
1.0* (1.00–1.10)

1.11* (0.96–1.07)

1.06* (1.00–1.10)

Adjusted for age, gender and BMI.

a

1.0 (0.99–1.01)

1.01 (1.00–1.02)

1.02 (0.99–1.05)

1.04 (0.96–1.12)

1.41** (1.15–1.73)

1.01* (1.00–1.01)

2.57** (1.46–4.53)

TNF-αa OR (95% CI)

0.98 (0.90–1.06)

1.0 (1.00–1.01)

1.0 (0.99–1.01)

1.0 (0.99–1.01)

1.01 (0.98–1.04)

1.1* (1.0–1.21)

1.22* (1.02–1.45)

1.12* (1.00–1.02)

1.87* (1.15–3.06)

IL-8a OR (95% CI)

LPO, lipid peroxidation; MDA PL, malondialdehyde in plasma; HbA1c (glycated hemoglobin); HOMA IR, Insulin resistance.

p < 0.0001.

p < 0.05;

**

*

1.05 (0.99–1.12)

1.1 (1.00–1.18)

1.2* (1.00–1.01)

1.11* (1.00–1.01)

TGL
BMI

1.0 (1.00–1.01)

1.00 (0.99–1.91)

LDL

1.0 (1.00–1.02)

1.00 (0.99–1.01)

Total Chol

1.0 (0.98–1.04)

1.00 (1.00–1.01)

1.01* (1.01–1.02)

1.9* (1.15–3.11)

3.17** (1.72–5.83)

Fasting glucose

MDA PL

Bold type indicates that the association reached statistical significance

Physical parameters

Lipoprotein profile

Diabetes status

LPO parameter

IL-6a OR (95% CI)

IL-1βa OR (95% CI)

1.02 (0.96–1.08)

1.04 (0.96–1.13)

1.12* (1.0–1.01)

1.0 (1.0–1.01)

1.0 (1.0–1.01)

1.0 (0.97–1.03)

1.07 (0.09–1.16)

1.19* (1.0–1.42)

1.21* (1.0–1.01)

1.91* (1.15–3.15)

IL-4a OR (95% CI)

Multivariate Logistic Regression model with the influence of lipid peroxidation, diabetes status, lipoprotein profile and physical parameters on plasma
cytokines.
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